Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors

被引:27
作者
Janssen, HLK
Hoebers, FJ
Sprong, D
Goethals, L
Williams, KJ
Stratford, IJ
Haustermans, KM
Balm, AJ
Begg, AC
机构
[1] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Div Head & Neck Oncol & Surg, NL-1066 CX Amsterdam, Netherlands
[3] Univ Hosp Gasthuisberg, Dept Radiotherapy, B-3000 Louvain, Belgium
[4] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
hypoxia; pimonidazole; nitroreductase; human;
D O I
10.1016/j.radonc.2003.09.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Hypoxia is a strong negative prognostic factor for all three major treatment modalities for cancer. The bioreductive drug pimonidazole is currently under clinical investigation as a hypoxia marker. In human head and neck tumors, in addition to staining patterns typical of chronic hypoxia, staining was seen specifically around areas of keratinization, raising the question of whether this is hypoxia-related. This could influence quantitative hypoxia estimates using this marker. We investigated here whether the differentiation-related staining was caused by locally high reductive enzyme levels. Patients and methods: The nitroterrazolium, compound NBT was used, which is reduced by nitroreductases to yield a blue color. The assay was validated on three genetically related MDA231 human mammary carcinoma cell lines: wildtype, overexpressing DT-diaphorase (DT1), and overexpressing cytochrome p450 reductase (R4). Increased NBT staining under normoxia was indeed seen for both R4 and DT1 lines. Pimonidazole staining under normoxia was only seen in the R4 line. Results: Frozen tumor sections from 20 patients with head and neck cancer injected with pimonidazole were incubated with NBT. Parallel sections were stained for pimonidazole. Staining patterns were then compared on matched images, and areas of keratinization scored for the presence or absence of pimonidazole and NBT. Pimonidazole staining was seen in 56% of keratinized areas, and of these, 78% showed increased NBT staining, indicating that high reductase levels are not a necessary requirement for differentiation-associated pimonidazole staining. In a second series, frozen sections of tumors from 15 patients not receiving pimonidazole were incubated with NBT and compared with staining after incubation with pimonidazole under both oxic and hypoxic conditions. Pimonidazole staining of some keratinizing areas under oxic conditions was seen. Of these areas, only a proportion (70%) showed increased NBT staining, confirming the lack of correspondence between keratin-associated pimonidazole staining and reductase levels. Conclusion: Hypoxia-independent pimonidazole staining can occur in more differentiated head and neck tumors, necessitating caution in hypoxia quantification. These data argue against a causative role for locally high reductase levels in differentiation-associated staining. DT-diaphorase appears to play no role in pimonidazole reduction. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:91 / 97
页数:7
相关论文
共 16 条
[1]   EVIDENCE THAT HYPOXIA MARKERS DETECT OXYGEN GRADIENTS IN LIVER - PIMONIDAZOLE AND RETROGRADE PERFUSION OF RAT-LIVER [J].
ARTEEL, GE ;
THURMAN, RG ;
YATES, JM ;
RALEIGH, JA .
BRITISH JOURNAL OF CANCER, 1995, 72 (04) :889-895
[2]   RETENTION OF MISONIDAZOLE IN NORMAL AND MALIGNANT-TISSUES - INTERPLAY OF HYPOXIA AND REDUCTASES [J].
COBB, LM ;
NOLAN, J ;
HACKER, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (04) :655-659
[3]   TISSUE DISTRIBUTION OF C-14-LABELED AND H-3 LABELED MISONIDAZOLE IN THE TUMOR-BEARING MOUSE [J].
COBB, LM ;
NOLAN, J ;
BUTLER, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (02) :347-351
[4]  
Cowen RL, 2003, MOL CANCER THER, V2, P901
[5]   RELATIONSHIP BETWEEN THE MELANIN CONTENT OF A HUMAN-MELANOMA CELL-LINE AND ITS RADIOSENSITIVITY AND UPTAKE OF PIMONIDAZOLE [J].
ELGAMOUSSI, R ;
THREADGILL, MD ;
PRADE, M ;
STRATFORD, IJ ;
GUICHARD, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 31 (04) :277-282
[6]   THE LABELING OF EMT-6 TUMORS IN BALB/C MICE WITH MISONIDAZOLE-C-14 [J].
GARRECHT, BM ;
CHAPMAN, JD .
BRITISH JOURNAL OF RADIOLOGY, 1983, 56 (670) :745-753
[7]   3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents:: mechanism of activation and cytotoxicity in vitro [J].
Jaffar, M ;
Phillips, RM ;
Williams, KJ ;
Mrema, I ;
Cole, C ;
Wind, NS ;
Ward, TH ;
Stratford, IJ ;
Patterson, AV .
BIOCHEMICAL PHARMACOLOGY, 2003, 66 (07) :1199-1206
[8]   HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors [J].
Janssen, HLK ;
Haustermans, KMG ;
Sprong, D ;
Blommestijn, G ;
Hofland, I ;
Hoebers, FJ ;
Blijweert, E ;
Raleigh, JA ;
Semenza, GL ;
Varia, MA ;
Balm, AJ ;
van Velthuysen, MLF ;
Delaere, P ;
Sciot, R ;
Begg, AC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (05) :1537-1549
[9]  
Kaanders JHAM, 2002, CANCER RES, V62, P7066
[10]   Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays [J].
Kennedy, AS ;
Raleigh, JA ;
Perez, GM ;
Calkins, DP ;
Thrall, DE ;
Novotny, DB ;
Varia, MA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (04) :897-905